Better Health. Better Life.

M Pharmaceutical Inc. Names Highly-Regarded Electrical Engineer Dr. Michel Fattouche to Its Advisory Board

Inventor and Co-Founder of Wi-LAN, Inc. Brings His Unique Combination of Pioneering Work, Research and Entrepreneurship to Canadian Biomedical Technology Company Focused on Obesity and Diabetes

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 19, 2015) - M Pharmaceutical Inc., (CSE:MQ)(OTCQB:MPHMF), (the "Company") a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, has named Dr. Michel Fattouche, a professor in the Department of Electrical and Computer Engineering at the University of Calgary, to the company's Advisory Board.

Dr. Fattouche, a registered Professional Engineer in the Province of Alberta, Canada, is a former "Calgarian of the Year" (2000) and "Prairies Entrepreneur of the Year" (2000) in Communications and Technology by Ernst and Young.

"Given the vision of the Company as a leader in biomedical products reliant on innovative technologies, it only adds to our strength by having somebody of Dr. Michel Fattouche's stature as one of our chief advisors," said Dr. Martin Mintchev, President & Chief Executive Officer of M Pharmaceutical, Inc. "We're very pleased to have Dr. Fattouche on our Advisory Board. His expertise and scope of knowledge in the field of electrical engineering and wireless communications will help us greatly as we move toward the final development and launch of technologies such as the e-Mosquito, gastro-intestinal neurostimulators and temporary controllable pseudobezoars."

The research work attributed to Dr. Fattouche has led to 21 patents being issued and 14 filed, including his pioneering work and patents in W-OFDM (Wide-band Orthogonal Frequency Division Multiplexing). That work led to his co-founding of the trail-blazing Wi-LAN Inc. in 1993. Wi-LAN's patented W-OFDM technology is being incorporated into the "WiMAX" Standard 802.16 developed by the Institute of Electrical and Electronics Engineers (IEEE).

Based on his related patents on Super-Resolution, Dr. Fattouche also co-founded Cell-Loc Inc. in 1995. Eight years later in 2003, Cell-Loc Inc. became Cell-Loc Location Technologies Inc., the developer of a family of network-based wireless location products that enable location-sensitive services.

The work of Dr. Fattouche has been widely cited internationally and he is viewed as a transformative leader in his field. He was named "Professor of the Year" by the Student Union for Teaching Excellence in the Department of Electrical and Computer Engineering at the University of Calgary in 1999.

"We welcome Dr. Fattouche to the M Pharmaceutical, Inc. Advisory Board that also includes research and technology leaders such as Dr. Douglas Janzen and Dr. Orly Yadid-Pecht," added Dr. Mintchev. "We're gratified to be able to rely on their expertise as we move forward in the development of the eMosquito, gastrointestinal neuro-stimulators and temporary controllable pseudobezoars."

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.

Forward Looking Statements:

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito, Trimeo and Trimtec biomedical technologies.

CONTACT INFORMATION

M Pharmaceutical Inc.
Investor Relations
604.428.0511
info@m-pharma.ca
www.m-pharma.ca
 

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.